MedTrace Logo

Evaluation of the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of Migraine

NCT05214001 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2025-05-31

No results posted yet for this study

Summary

In a real-world population of adults with migraine, the investigators would like to investigate whether 12.5 mg almotriptan is non-inferior to 50 mg ubrogepant in terms of pain freedom at 2 hours after drug intake.

Conditions

  • Migraine With Aura
  • Migraine Without Aura

Interventions

DRUG

Almotriptan 12.5 Mg Oral Tablet

Treatment for an acute, moderate to severe migraine attack

DRUG

Ubrogepant 50Mg Tab

Treatment for an acute, moderate to severe migraine attack

Sponsors & Collaborators

  • Messoud Ashina, MD

    lead OTHER

Principal Investigators

  • Messoud Ashina, Prof. · Danish Headache Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-30
Primary Completion
2024-04-15
Completion
2024-04-15
FDA Drug
Yes

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05214001 on ClinicalTrials.gov